Biotechnology · Boston, Massachusetts, United States
$3.43
+7.37% (+$0.23)2026-08-25
Smart-Money SignalNeutral · 52/100— Insider open-market flow is flat over 90 days
Net Income-$17.8M
EPS$-0.51
Market Cap$237.2M
Price Performance
Historical data including institutional events
Company Profile
J
James McArthur
CEO & Executive Director
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
